What is next in ALS clinical trials?

Neurology

Volumn 69, Issue 8, 2007, Pages 719-720

  Sorenson, Eric J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; MESSENGER RNA;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL FEATURE; CLINICAL RESEARCH; CLINICAL TRIAL; EDITORIAL; HUMAN; MOTONEURON; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RNA INTERFERENCE; SURVIVAL RATE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; TREATMENT FAILURE;

EID: 34548126496     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000271093.41793.ff     Document Type: Editorial

References (9)

1. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;69:776-784.
2. Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709-714.
3. Kasarskis EJ, Dempsey-Hall L, Thompson MM, Luu LC, Mendiondo M, Kryscio R. Rating the severity of ALS by caregivers over the telephone using the ALSFRS-R. Amyotrophic Lateral Sclerosis Other Motor Neuron Disorders 2005;6:50-54.
4. Montes J, Levy G, Albert S, et al. Development and evaluation of a self-administered version of the ALSFRS-R. Neurology 2006;67:1294-1296.
5. Great Lakes ALSSG. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis [see comment]. Neurology 2003;61:1503-1507.
6. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842.
7. Manabe Y, Nagano I, Gazi MS, et al. Adenovirus-mediated gene transfer of glial cell line-derived neurotrophic factor prevents motor neuron loss of transgenic model mice for amyotrophic lateral sclerosis. Apoptosis 2002;7:329-334.
8. Xia XG, Zhou H, Zhou S, Yu Y, Wu R, Xu Z. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase [erratum appears in 2005;92:1554]. J Neurochem 2005;92:362-367.
9. Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat Med 2005;11:429-433.